‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1" is generating significant coverage in the Business category, with 9 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Boston Globe, NewsNation, ABC News - Breaking News, Latest News and Videos and Yahoo. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 54d ago.
Quick answers
Why is "‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taki" trending?
Because 9 independent news sources published 9 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- Could GLP-1s be linked to a rare type of vision loss? Here’s what to know. The Boston Globe · 56d ago
- Patients sue GLP-1 makers over sudden loss of vision NewsNation · 56d ago
- What GLP-1 users should know about the potential risk of a rare type of vision loss ABC News - Breaking News, Latest News and Videos · 56d ago
- Hundreds of lawsuits filed against some GLP-1 Makers over vision loss Yahoo · 56d ago
- Patients sue GLP-1 makers over risk of blindness WSOC TV · 56d ago
- Vision loss concerns spark US lawsuits as Australian bodies issue advice on GLP-1 drugs insightnews.com.au · 56d ago
- Are GLP-1s causing blindness? What we know about rare cases USA Today · 56d ago
- Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss WSJ · 56d ago
- ‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1 Boston 25 News · 56d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.